|
Market Cap | 1.86B | EPS (ttm) | - |
P/E | - | EPS this Y | 62.81% |
Forward P/E | 67.23 | EPS next Y | 139.68% |
PEG | - | EPS past 5Y | - |
P/S | - | EPS next 5Y | - |
P/B | 1.54 | EPS Q/Q | -42.33% |
Dividend | - | Sales Q/Q | 16.51% |
Insider Own | 5.18% | Inst Own | 0.30% |
Insider Trans | 0.00% | Inst Trans | - |
Short Float | 0.02% | Earnings | Nov 08/b |
Analyst Recom | 1.40 | Target Price | 14.03 |
Avg Volume | 52.82K | 52W Range | 6.83 - 13.49 |
|
|
|
Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany. |
|
|
|
Market Cap | 18.49M | EPS (ttm) | -0.45 |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | -41.17% |
P/S | - | EPS next 5Y | - |
P/B | 1.38 | EPS Q/Q | 44.61% |
Dividend | - | Sales Q/Q | - |
Insider Own | 64.25% | Inst Own | 9.91% |
Insider Trans | 0.00% | Inst Trans | 0.48% |
Short Float | 9.01% | Earnings | Mar 27/a |
Analyst Recom | 2.00 | Target Price | 7.00 |
Avg Volume | 574.00K | 52W Range | 0.19 - 3.10 |
|
|
|
Vaxxinity, Inc. is a biotechnology company that aims to democratize health by bringing the efficiency of vaccines to chronic diseases. The company uses its synthetic peptide vaccine platform to harness the immune system and convert the body into its own 'drug factory', stimulating the production of antibodies with a therapeutic effect. Its current pipeline consists of five chronic disease candidates from early to late-stage development across multiple therapeutic areas including Alzheimer's, Parkinson's, migraine and hypercholesterolemia as well as a candidate for COVID-19 prevention. The company was founded by Louis G. Reese IV and Mei Mei Hu in 2014 and is headquartered in Exploration Park, FL. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Prime Movers Lab Fund I LP | 10% Owner | Sep 08 '23 | Sale | 1.67 | 25,089 | 41,899 | 8,713,663 | Sep 08 06:05 PM | Prime Movers Lab Fund I LP | 10% Owner | Sep 08 '23 | Sale | 1.67 | 22,872 | 38,196 | 831,658 | Sep 08 06:05 PM | Prime Movers Lab Fund I LP | 10% Owner | Sep 07 '23 | Sale | 1.79 | 20,312 | 36,302 | 8,738,752 | Sep 08 06:05 PM | Prime Movers Lab Fund I LP | 10% Owner | Sep 07 '23 | Sale | 1.79 | 18,516 | 33,092 | 834,053 | Sep 08 06:05 PM | Prime Movers Lab Fund I LP | 10% Owner | Sep 06 '23 | Sale | 1.88 | 5,308 | 9,991 | 8,759,064 | Sep 08 06:05 PM |
|
|
|
|
Market Cap | 3.45M | EPS (ttm) | -0.25 |
P/E | - | EPS this Y | 29.17% |
Forward P/E | - | EPS next Y | 76.47% |
PEG | - | EPS past 5Y | 38.93% |
P/S | 0.36 | EPS next 5Y | - |
P/B | 0.07 | EPS Q/Q | - |
Dividend | - | Sales Q/Q | -0.22% |
Insider Own | 1.86% | Inst Own | 11.14% |
Insider Trans | 0.00% | Inst Trans | -0.67% |
Short Float | 0.04% | Earnings | Oct 27/a |
Analyst Recom | 1.00 | Target Price | 10.00 |
Avg Volume | 706.81K | 52W Range | 0.09 - 0.45 |
|
|
|
Recon Technology Ltd. engages in providing oilfield services. It operates through the following segments: Automation Product and Software, Equipment and Accessories, Oilfield Environmental Protection, and Platform Outsourcing Services. The Automation Product and Software segment is involved in the sale of automation products specialized equipment when combined with services represent a single performance obligation for the development and construction of a single asset. The Equipment and Accessories segment includes the delivery of standard or customized products and equipment, including automation products, furnaces, and related accessories. The Oilfield Environmental Protection segment focuses on the wastewater treatment products and related service to oilfield and chemical industry companies. The Platform Outsourcing Services segment refers to online platform development, maintenance, and operation services to gas stations around different provinces in China. The company was founded by Guang Qiang Chen, Hong Qi Li, and Shen Ping Yin on August 21, 2007 and is headquartered in Beijing, China. |
|
| |
|
Market Cap | - | EPS (ttm) | - |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | - |
P/S | - | EPS next 5Y | - |
P/B | - | EPS Q/Q | - |
Dividend | - | Sales Q/Q | - |
Insider Own | - | Inst Own | - |
Insider Trans | - | Inst Trans | - |
Short Float | - | Earnings | - |
Analyst Recom | - | Target Price | - |
Avg Volume | 7.02M | 52W Range | 3.84 - 11.39 |
|
|
|
NCI is a one-stop apparel solution services provider. We offer a full suite of services in the apparel supply chain, including market trend analysis, product design and development, raw material sourcing, production and quality control, and logistics management serving customers located in the European and North American markets through Neo-Concept HK. |
|
|
|
Market Cap | 4.03M | EPS (ttm) | -1.78 |
P/E | - | EPS this Y | 58.16% |
Forward P/E | - | EPS next Y | 9.76% |
PEG | - | EPS past 5Y | 50.07% |
P/S | - | EPS next 5Y | - |
P/B | 1.47 | EPS Q/Q | -93.89% |
Dividend | - | Sales Q/Q | - |
Insider Own | 11.82% | Inst Own | 2.79% |
Insider Trans | -10.55% | Inst Trans | 4.58% |
Short Float | 0.73% | Earnings | Mar 18/a |
Analyst Recom | 1.00 | Target Price | 0.75 |
Avg Volume | 1.52M | 52W Range | 0.11 - 1.25 |
|
|
|
Avenue Therapeutics, Inc. is a specialty pharmaceutical company, which engages in acquiring, licensing, and commercializing products for use in the intensive care hospital setting. It focuses on the development of intravenous tramadol, a potential alternative that could reduce the use of conventional opioids for patients suffering from acute pain. The company was founded on February 9, 2015 and is headquartered in Bay Harbor Islands, FL. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Davidow Robert L | 10% Owner | Dec 11 '23 | Sale | 0.14 | 353,000 | 49,600 | 22,000 | Dec 13 04:02 PM | Davidow Robert L | 10% Owner | Dec 11 '23 | Sale | 0.14 | 264,000 | 36,960 | 681,000 | Dec 13 04:02 PM | Fortress Biotech, Inc. | 10% Owner | Sep 08 '23 | Buy | 0.72 | 418,410 | 301,255 | 1,032,390 | Sep 12 09:02 AM | ROSENWALD LINDSAY A MD | Director | Sep 08 '23 | Buy | 0.72 | 348,675 | 251,046 | 354,318 | Sep 12 09:03 AM |
|
|
| |
|
Market Cap | 73.74M | EPS (ttm) | -0.80 |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | - |
P/S | 1.65 | EPS next 5Y | 24.57% |
P/B | 8.67 | EPS Q/Q | -264.10% |
Dividend | - | Sales Q/Q | 115.11% |
Insider Own | 0.95% | Inst Own | 12.68% |
Insider Trans | 0.00% | Inst Trans | -4.69% |
Short Float | 1.66% | Earnings | Mar 28/a |
Analyst Recom | 1.00 | Target Price | 4.50 |
Avg Volume | 1.21M | 52W Range | 0.96 - 12.04 |
|
|
|
NaaS Technology, Inc. engages in the provision of electric vehicle charging services. The firm maintains an EV charging network in China through its charging network for third-party charging station operators, and the number of public DCFCs (direct current fast charger with 30kW power output or more) connected to its network. The company was founded by Zhen Dai and Yang Wang on July 16, 2013 and is headquartered in Beijing, China. |
|
|
|
Market Cap | 115.29M | EPS (ttm) | -0.00 |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | - |
P/S | - | EPS next 5Y | - |
P/B | 1.46 | EPS Q/Q | -197.91% |
Dividend | - | Sales Q/Q | - |
Insider Own | 54.10% | Inst Own | 5.82% |
Insider Trans | 0.00% | Inst Trans | 5.84% |
Short Float | 0.07% | Earnings | - |
Analyst Recom | - | Target Price | - |
Avg Volume | 77.59K | 52W Range | 4.15 - 19.75 |
|
|
|
Brand Engagement Network, Inc. engages in the provision of conversational artificial intelligence assistants with the purpose of transforming engagement and analytics for businesses through security-focused, multimodal communication and human-like artificial intelligence assistants. The firm is also involved in delivering highly personalized, multi-modal artificial intelligence engagement with a focus on industries where there is a massive workforce gap and an opportunity to transform how consumers engage with networks, providers, and brands. The company is headquartered in Jackson, WY. |
|
| |
|
Market Cap | 1.02M | EPS (ttm) | -19.05 |
P/E | - | EPS this Y | 115.79% |
Forward P/E | 0.06 | EPS next Y | 466.67% |
PEG | - | EPS past 5Y | 73.50% |
P/S | 0.04 | EPS next 5Y | - |
P/B | 0.01 | EPS Q/Q | 94.97% |
Dividend | - | Sales Q/Q | 94.94% |
Insider Own | 4.14% | Inst Own | 11.83% |
Insider Trans | 292.78% | Inst Trans | - |
Short Float | 0.74% | Earnings | Mar 28/b |
Analyst Recom | 1.00 | Target Price | 300.00 |
Avg Volume | 746.58K | 52W Range | 1.15 - 140.00 |
|
|
|
Sunshine Biopharma, Inc. is a pharmaceutical company, which engages in the research, development, and commercialization of oncology and antiviral drugs. It is also involved in the development and commercialization of science-based nutritional supplements. The firm's product includes treatment for Coronavirus infections and anticancer drugs. The company was founded on August 31, 2006 and is headquartered in New York, NY. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Slilaty Steve N. | Chief Executive Officer | Mar 04 '24 | Buy | 0.10 | 100,000 | 10,000 | 130,000 | Mar 05 04:05 PM | Slilaty Steve N. | Chief Executive Officer | Feb 08 '24 | Buy | 0.10 | 20,000 | 2,000 | 30,000 | Feb 12 04:05 PM |
|
|
|
|
Market Cap | 10.96M | EPS (ttm) | -0.98 |
P/E | - | EPS this Y | 23.89% |
Forward P/E | - | EPS next Y | 25.58% |
PEG | - | EPS past 5Y | 41.24% |
P/S | 0.21 | EPS next 5Y | 10.00% |
P/B | 0.27 | EPS Q/Q | -912.00% |
Dividend | - | Sales Q/Q | -52.39% |
Insider Own | 15.90% | Inst Own | 8.20% |
Insider Trans | 0.00% | Inst Trans | -69.35% |
Short Float | 2.74% | Earnings | Feb 14/a |
Analyst Recom | 1.00 | Target Price | 7.75 |
Avg Volume | 647.65K | 52W Range | 0.94 - 8.40 |
|
|
|
Cineverse Corp. is a global streaming technology and entertainment company. It owns and operates streaming channels, all powered by its advanced, proprietary technology platform. The firm currently features enthusiast brands for subscription video on demand (SVOD), advertising-based video on demand (AVOD), and free, ad-supported streaming television (FAST) channels. It entertains consumers around the globe by providing premium feature films and television series, enthusiast streaming channels, and technology services to some media, retail, and technology companies. The company was founded by A. Dale Mayo on March 31, 2000 and is headquartered in New York, NY. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Lindsey Mark Wayne | CFO | Sep 29 '23 | Buy | 1.15 | 10,000 | 11,500 | 18,631 | Oct 03 08:29 PM |
|
|
|
|
Market Cap | 4.08M | EPS (ttm) | -0.55 |
P/E | - | EPS this Y | 14.47% |
Forward P/E | - | EPS next Y | 18.46% |
PEG | - | EPS past 5Y | 45.52% |
P/S | 0.45 | EPS next 5Y | - |
P/B | 0.77 | EPS Q/Q | 70.94% |
Dividend | - | Sales Q/Q | -83.07% |
Insider Own | 12.32% | Inst Own | 18.63% |
Insider Trans | 0.00% | Inst Trans | 49.85% |
Short Float | 1.82% | Earnings | Feb 08/a |
Analyst Recom | 1.00 | Target Price | 2.25 |
Avg Volume | 135.50K | 52W Range | 0.28 - 1.86 |
|
|
|
Applied DNA Sciences, Inc. engages in developing and marketing technologies to produce and detect deoxyribonucleic acid. It operates through the following segments: Therapeutic DNA Production, MDx Testing Services, and DNA Tagging and Security Products and Services. The Therapeutic DNA Production segment offers DNA detection via PCR to provide and develop clinical molecular diagnostics and genetic testing services. The MDx Testing Services segment is involved in performing and developing clinical molecular diagnostic tests and clinical laboratory testing services. The DNA Tagging and Security Products and Services segment includes manufacture and detection of DNA for industrial supply chain security services. The company was founded in 1983 and is headquartered in Stony Brook, NY. |
|
|